Despite failing to achieve one of the co-primary endpoints of the SENTRY study, Karyopharm will still approach the FDA for its sNDA.
Myelofibrosis morbidity is driven by splenomegaly, systemic symptoms, and anemia; discontinuation of JAK inhibitors exceeds ...
March 24 (Reuters) - Karyopharm Therapeutics said on Tuesday its therapy for patients with a rare blood cancer showed a reduction in spleen size in a late-stage trial, meeting one of the two main ...
March 24 (Reuters) - Karyopharm Therapeutics said on Tuesday its oncology therapy showed a statistically significant improvement in spleen volume in a late‑stage trial in patients with a rare blood ...
Karyopharm Therapeutics said on Tuesday its oncology therapy showed a statistically significant improvement in spleen ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results